Aesculap AG

A Novel System for Monitoring Intracranial Pressure in Hydrocephalus Patients CENTER VALLEY, Pa., Aug. 27, 2024 /PRNewswire/ -- Aesculap, Inc. (Aesculap), in partnership with Christoph Miethke GmbH & Co. KG (MIETHKE), announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation for the M.scio® System. This unique, non-invasive, telemetric pressure measurement system is designed to provide continuous access to long-term, intracranial pressure (ICP) monitoring of cerebrospinal fluid (CSF) for the management of hydrocephalus via a permanent, fully implantable sensor. The Breakthrough Device Program is a voluntary program designed to expedite the development and review of medical devices that may provide more effective treatment or diagnosis of a life-threatening or irreversibly debilitating disease. Receiving this designation is a testament to the joint commitment of Aesculap and MIETHKE to improve the lives of patients living with hydrocephalus. "The Breakthrough Device Designation is an important step forward toward recognizing the need for equipping neurosurgeons with an innovative technology to improve care for hydrocephalus patients in the U.S.," said Bob Sowinski, Corporate Vice President, Aesculap. "The current approach to ICP monitoring has limitations that the M.scio System is designed to overcome. Receiving this designation from the FDA is an acknowledgement from the agency that the device has the potential to provide a more effective treatment than existing options." Hydrocephalus is a condition characterized by a buildup of fluid in the brain that affects mostly babies, but it can affect people at any age. It is estimated that two out of every 1,000 babies are born with hydrocephalus. If left untreated, it can lead to serious consequences, including learning or physical disabilities and even death.1 "Advances in shunt technology, particularly adjustable gravitational valves, have significantly improved patient outcomes," said Christoph Miethke, CEO and founder of MIETHKE. "However, adjusting valves without knowing the ICP values based on a patient's body position can lead to incorrect valve adjustments. The M.scio System is designed to provide an alternative treatment option to the currently available ICP monitoring modalities. In this way, the M.scio System is designed to guide both surgical as well as medical treatment and optimize patient management. MIETHKE strives to develop technologies that enable all hydrocephalus patients worldwide to live a normal life. That's what matters and what drives us to innovate and challenge the status quo." About Aesculap, Inc. Aesculap, Inc., a B. Braun company, is part of a 180-year-old global organization focused on meeting the needs of an ever-changing healthcare community. Through close collaboration with its customers, Aesculap provides advanced technologies for neurosurgery, general surgery and sterilization technologies. Aesculap continues a proud heritage of leadership and responsiveness as we strive to deliver products and services that improve the quality of patients' lives. For more information, call 800-282-9000 or visit aesculapusa.com. About Christoph Miethke GmbH & Co. KG Since 1992, MIETHKE has been developing and manufacturing neurosurgical implants, especially for the treatment of hydrocephalus. Our vision is to develop technologies that enable all hydrocephalus patients worldwide to live a normal life. Every step in this direction is the right one and drives us to continue with further research, to make products even better and to question solutions again and again. We listen carefully to our partners, neurosurgeons and patients as well as to each other in order to learn and allow room for ideas. We are aware of the importance of our work for patients' lives and share this responsibility. For more information, call +49 331 620830 or visit miethke.com. Reference: Hydrocephalus | National Institute of Neurological Disorders and Stroke. . . SOURCE Aesculap, Inc.

CENTER VALLEY, Pa., April 16, 2024 /PRNewswire/ -- Aesculap, Inc. (Aesculap), a market leader in sterile container systems, has launched AESCULAP Aicon® RTLS, which pairs real-time location service (RTLS) technology with the AESCULAP Aicon® Sterile Container System to help improve the efficiency of Sterile Processing Departments (SPD). Aesculap will debut this new technology at the Healthcare Sterile Processing Association (HSPA) annual conference held April 21-23 in Las Vegas, NV. "AESCULAP Aicon RTLS enables us to reach new levels of operational efficiencies. It provides operating room and SPD leaders with knowledge at every step of the instrument reprocessing life cycle, automatically communicating real-time location data of surgical instrument sets for more informed decision-making and resource management. It's a significant enhancement to our recent AESCULAP Aicon Sterile Container System. The addition of real-time tracking technology can help reduce the risk of surgical case delays and errors," said Alan Stout, Vice President of Strategic Sales. Attaching Aesculap's sterilizable Bluetooth® Technology beacon to the container system unlocks the data and insights that can help avoid surgical delays, reduce manual processes and streamline processing workflows. Designed for easy deployment and intuitiveness, this technology serves as a user-friendly tool to help ensure the right sets will be available where and when they are needed. "As the long-standing market leader in sterile containers, the launch of AESCULAP Aicon RTLS merges our historic strengths with the forefront of real-time tracking technology. It's more than just an extension of our recent container system launch. We're aiming to change the very fabric of surgical instrument set management to meet and exceed the needs of operating rooms and Sterile Processing Departments nationwide," said Bob Sowinski, Corporate Vice President, Aesculap. HSPA attendees can stop by Booth #400 for an interactive, hands-on experience with AESCULAP Aicon RTLS. For more information, please visit our website. About Aesculap, Inc. Aesculap, Inc., a B. Braun company, is part of a 180-year-old global organization focused on meeting the needs of an ever-changing healthcare community. Through close collaboration with its customers, Aesculap provides advanced technologies for neurosurgery, general surgery and sterilization technologies. Aesculap continues a proud heritage of leadership and responsiveness as we strive to deliver products and services that improve the quality of patients' lives. For more information, call 800-282-9000 or visit aesculapusa.com. View original content to download multimedia: SOURCE Aesculap, Inc.

The first and only neutral needleless connector not made with BPA and manufactured with drug-resistant material¹ BETHLEHEM, Pa., Dec. 14, 2023 /PRNewswire/ -- B. Braun Medical Inc. (B. Braun), a leader in smart infusion therapy and pain management, announced today the launch of its new CARESITE Micro™ Luer Access Device, designed to reduce exposure to harmful chemicals and decrease infection risk, making IV access safer for patients and healthcare providers. The CARESITE Micro Device is the only needleless connector not made with Bisphenol A (BPA), a harmful chemical known to cause multi-organ toxicity.1 Made with a drug-resistant material, the CARESITE Micro Device can help reduce the risk of infections and drug exposure resulting from stress cracks associated with material and drug incompatibility.1 Hospital-acquired bloodstream infections (HA-BSIs), which are often associated with catheter insertions, remain a major cause of morbidity and mortality.2 The CARESITE Micro Device features a smooth, flat surface that allows proper disinfection, and a straight fluid path design that helps complete flushing of blood and medications with a small flush volume,1 helping to reduce the risk of HA-BSI. "We are excited to introduce the CARESITE Micro Luer Access Device. Helping to reduce HA-BSIs and accidental drug exposure supports our commitment to the safety of the patients and providers we serve," said Angela Karpf, MD, Corporate Vice President, Medical Affairs. For more information, visit our website. About B. Braun B. Braun Medical Inc. (B. Braun) is a leader in smart infusion therapy and safe and effective pharmacy products, patient and provider safety, and sustainable health solutions. Our purpose is to help providers constantly improve patient satisfaction and outcomes. With products and services created to help healthcare professionals focus on what matters most—their patients—we're uniquely positioned to help health systems succeed now and in the future. B. Braun is headquartered in Bethlehem, Pennsylvania and is part of the B. Braun Group of Companies in the U.S., which includes B. Braun Interventional Systems, Aesculap ® and CAPS ®. The company employs 8,500 people at over 30 locations across North America. Globally, the B. Braun Group of Companies employs more than 64,000 employees in 64 countries. Guided by its Sharing Expertise ® philosophy, B. Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs. To learn more about B. Braun Medical, explore our website. ¹ B. Braun Data on File ² Manzoor, Muhammad Faisal et al. "An insight into bisphenol A, food exposure and its adverse effects on health: A review." Frontiers in nutrition vol. 9 1047827. 3 Nov. 2022, doi: 10.3389/fnut.2022.1047827 SOURCE B. Braun Medical Inc.